Fast Five Quiz: Castration-Resistant Metastatic and Advanced Prostate Cancer Management

Evelyn S. Marienberg, MD

Disclosures

November 08, 2022

If provided enough time, all patients with metastatic disease become resistant to androgen ablation.

After a rise in PSA level > 4 ng/dL, the median time to symptomatic progression is 6-8 months, according to Terris and colleagues. Further, median time to death after a PSA rise is 12-18 months. Survival is < 1 year once the patient exhibits symptoms, per the same authors.

Learn more about the management of metastatic CRPC.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....